JP2017515799A - コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９ - Google Patents

コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９ Download PDF

Info

Publication number
JP2017515799A
JP2017515799A JP2016560760A JP2016560760A JP2017515799A JP 2017515799 A JP2017515799 A JP 2017515799A JP 2016560760 A JP2016560760 A JP 2016560760A JP 2016560760 A JP2016560760 A JP 2016560760A JP 2017515799 A JP2017515799 A JP 2017515799A
Authority
JP
Japan
Prior art keywords
plantarum inducia
clostridium difficile
difficile
food
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016560760A
Other languages
English (en)
Japanese (ja)
Inventor
ミケルサール マリカ
ミケルサール マリカ
ソンギセップ エップ
ソンギセップ エップ
ラトセプ メール
ラトセプ メール
ヒュート ピーリョ
ヒュート ピーリョ
シュミット インビ
シュミット インビ
トラッサル カイ
トラッサル カイ
セップ エップ
セップ エップ
ミケルサール ライク−ヒオ
ミケルサール ライク−ヒオ
キルク カレ
キルク カレ
ストセペトバ ジェレナ
ストセペトバ ジェレナ
コルジャルグ シーリ
コルジャルグ シーリ
ヴァラス マルジャム
ヴァラス マルジャム
Original Assignee
オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス
オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/244,284 external-priority patent/US20140335066A1/en
Application filed by オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス, オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス filed Critical オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス
Publication of JP2017515799A publication Critical patent/JP2017515799A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2016560760A 2014-04-03 2014-10-31 コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９ Pending JP2017515799A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/244,284 US20140335066A1 (en) 2008-05-13 2014-04-03 Lactobacillus plantarum inducia dsm 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against clostridium difficile
US14/244,284 2014-04-03
PCT/EE2014/000007 WO2015149818A1 (en) 2014-04-03 2014-10-31 Lactobacillus plantarum inducia strain dsm 21379 as hypocholesterolemic agent and antimicrobial agent against clostridium difficile

Publications (1)

Publication Number Publication Date
JP2017515799A true JP2017515799A (ja) 2017-06-15

Family

ID=51932160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560760A Pending JP2017515799A (ja) 2014-04-03 2014-10-31 コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９

Country Status (3)

Country Link
JP (1) JP2017515799A (et)
EE (1) EE05799B1 (et)
WO (1) WO2015149818A1 (et)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365420B1 (ko) * 2022-01-04 2022-02-23 주식회사 바이오뱅크힐링 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519326D0 (en) 2015-11-02 2015-12-16 Optibiotix Health Ltd Composition`
GB201611782D0 (en) * 2016-07-06 2016-08-17 Optibiotix Ltd Composition
CN112823015A (zh) * 2018-08-01 2021-05-18 N.M.B.医学应用有限公司 减少卡路里的吸收和改变所消耗的营养物的营养价值的口服施用的补充剂及方法
CN109234189A (zh) * 2018-08-17 2019-01-18 甘肃普诺贝康生物科技有限责任公司 一株具有抗氧化能力的植物乳杆菌菌株bx62及其应用
WO2020171256A1 (ko) * 2019-02-21 2020-08-27 서울대학교산학협력단 클로스트리디움 디피실레(clostridium difficile) 성장 억제효과를 갖는 락토바실러스 균주
CN116676239B (zh) * 2023-07-26 2023-10-27 杭州微致生物科技有限公司 一种植物乳杆菌vb165及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518113A (ja) * 2008-01-15 2011-06-23 エムデーツェー マックス−デルブリュック−ツェントゥルム フュア モレキュラーレ メディツィーン ベルリン−ブーフ アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド
US20110274789A1 (en) * 2008-05-13 2011-11-10 Marika Mikelsaar Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it
JP2013507332A (ja) * 2009-10-09 2013-03-04 エービー−バイオティクス，エセ．ア． コレステロール低下剤としてのラクトバチルス・プランタルム菌株

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518113A (ja) * 2008-01-15 2011-06-23 エムデーツェー マックス−デルブリュック−ツェントゥルム フュア モレキュラーレ メディツィーン ベルリン−ブーフ アドレナリン受容体のα１ループ２またはβ２ループ１上のエピトープを認識する抗体に対して結合親和性を有するペプチド
US20110274789A1 (en) * 2008-05-13 2011-11-10 Marika Mikelsaar Isolated lactobacillus plantarum strain inducia dsm 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it
JP2013507332A (ja) * 2009-10-09 2013-03-04 エービー−バイオティクス，エセ．ア． コレステロール低下剤としてのラクトバチルス・プランタルム菌株

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL DAILY JOURNAL, vol. Vol.16, JPN6018014086, 2006, pages 1018 - 1028 *
JOURNAL OF CARDIOLOGY, vol. Vol.62, JPN6018014090, 2013, pages 374 - 378 *
高橋伸一郎: "酸化ストレスとインスリン様活性の相互作用が健康寿命延伸に果たす役割 Interplay between oxidative s", 医学のあゆみ, vol. 247, no. 9, JPN6018014088, 2013, pages 934 - 941 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102365420B1 (ko) * 2022-01-04 2022-02-23 주식회사 바이오뱅크힐링 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도

Also Published As

Publication number Publication date
EE201400038A (et) 2015-11-16
EE05799B1 (et) 2017-10-16
WO2015149818A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
EP3193895B1 (en) Lactobacillus plantarum inducia strain dsm 21379 as hypocholesterolemic agent and antimicrobial agent against clostridium difficile
US11701396B2 (en) Treatment of Clostridium difficile infection
Sirilun et al. Characterisation of non human origin probiotic Lactobacillus plantarum with cholesterol-lowering property
Ebel et al. Impact of probiotics on risk factors for cardiovascular diseases. A review
Kondepudi et al. Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile
JP2017515799A (ja) コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９
Kim et al. Physiological characteristics and anti-obesity effect of Lactobacillus plantarum K10
Santos et al. Safety, beneficial and technological properties of Enterococcus faecium isolated from Brazilian cheeses
US20130336931A1 (en) Synbiotic compositions for restoration and reconstitution of gut microbiota
Bendali et al. Beneficial effects of a strain of Lactobacillus paracasei subsp. paracasei in Staphylococcus aureus-induced intestinal and colonic injury
CN112204129A (zh) 植物乳杆菌kbl396菌株及其用途
Klayraung et al. Antibacterial and antioxidant activities of acid and bile resistant strains of Lactobacillus fermentum isolated from miang
Zhang et al. Lactobacillus reuteri ATCC 55730 and L22 display probiotic potential in vitro and protect against Salmonella-induced pullorum disease in a chick model of infection
Mahdi et al. Antibacterial immunomodulatory and antibiofilm triple effect of Salivaricin LHM against Pseudomonas aeruginosa urinary tract infection model
US11730780B2 (en) Lactic acid bacteria, methods and uses thereof
Mansour et al. Inhibition of Clostridium difficile in mice using a mixture of potential probiotic strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: novel candidates to control C. difficile infection (CDI)
Damodharan et al. In vitro probiotic characterization of Lactobacillus strains from fermented radish and their anti-adherence activity against enteric pathogens
Evivie et al. Suppressive effects of Streptococcus thermophilus KLDS 3.1003 on some foodborne pathogens revealed through in vitro, in vivo and genomic insights
Mahdi et al. Establishing novel roles of bifidocin LHA, antibacterial, antibiofilm and immunomodulator against Pseudomonas aeruginosa corneal infection model
KR101809616B1 (ko) 항비만효과를 가지는 케피어 유래 프로바이오틱 균주
Lim et al. Synergy effects by combination with lactic acid bacteria and frutooligosaccharides on the cell growth and antimicrobial activity
Mukdsi et al. Feruloyl esterase activity is influenced by bile, probiotic intestinal adhesion and milk fat
Hou et al. Characteristics of cholesterol-lowering Lactobacillus casei subsp. casei strain GL-03 isolated from cheese
Pagliaro et al. The use of probiotics in gastrointestinal diseases
Islam et al. Lemon juice synergistically preserved with lactobacilli ameliorates inflammation in shigellosis mice

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190212